Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer's Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023

- The proof-of-concept open-label study evaluated the safety and tolerability, regulatory T cell function, blood biomarkers, and preliminary efficacy of COYA 301 in eight patients with... | March 31, 2023

Related Keywords

Canada ,Texas ,United States ,Houston ,United Kingdom ,British ,Alireza Faridar ,Stanley Appel ,Stanleyh Appel Department Of Neurology ,Ann Kimball Johnw Johnson Center ,Houston Methodist Research Institute ,Nasdaq ,Coya Therapeutics Inc ,Coya Therapeutics ,Symposia Neurodegeneration ,New Biology Guiding ,Next Generation ,Therapeutic Development ,British Columbia ,Mini Mental State Examination ,Clinical Dementia Rating ,Scientific Advisory Board ,Ann Kimball ,Cellular Therapeutics ,Weill Cornell Medical College ,Gary Edwards Distinguished Chair ,Houston Methodist Research ,Regulatoryt Cell Expansion Strategy ,Target Inflammation ,Nc Stock Exchange ,News ,Information ,Press Release ,The ,Study ,Revaluated ,Safety ,End ,Egulatory , ,Fell ,Flood ,Reliminary ,Efficacy ,F ,Hoya ,01 ,N ,Flight ,Atients Coya Us22407b1089 ,